MBCT w depresji trudnej do leczenia: metaanaliza danych indywidualnych pacjentów

Wykaz prac cytowanych wewnątrz artykułu (relacja cites → Publication), pobrany ze zweryfikowanych metadanych PubMed / Crossref:

1. McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394–412.
   pubmed_reference_list
2. Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–17.
   pubmed_reference_list
3. Cuijpers P, Miguel C, Harrer M, Plessen CY, Ciharova M, Papola D, et al. Psychological treatment of depression: a systematic overview of a ‘Meta-Analytic Research Domain. J Affect Disord. 2023;335:141–51.
   pubmed_reference_list
4. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357–66.
   pubmed_reference_list
5. Rush AJ, Sackeim HA, Conway CR, Bunker MT, Hollon SD, Demyttenaere K, et al. Clinical research challenges posed by difficult-to-treat depression. Psychol Med. 2022;52(3):419–32.
   pubmed_reference_list
6. McAllister-Williams RH, Arango C, Blier P, Demyttenaere K, Falkai P, Gorwood P, et al. The identification, assessment and management of difficult-to-treat depression: an international consensus statement. J Affect Disord. 2020;267:264–82.
   pubmed_reference_list
7. McHugh RK, Whitton SW, Peckham AD, Welge JA, Otto MW. Patient preference for psychological vs pharmacologic treatment of psychiatric disorders: a meta-analytic review. J Clin Psychiatry. 2013;74(6):595–602.
   pubmed_reference_list
8. Segal ZV, Williams JMG, Teasdale J. Mindfulness-Based cognitive therapy for depression. 2nd ed. New York: Guilford Press; 2013.
   pubmed_reference_list
9. National Institute for Health and Clinical Excellence (NICE) . Depression in adults: treatment and management. 2022. Available from: https://www.nice.org.uk/guidance/ng222
   pubmed_reference_list
10. Eisendrath SJ, Gillung E, Delucchi KL, Segal ZV, Nelson JC, McInnes LA, et al. A randomized controlled trial of mindfulness-based cognitive therapy for treatment-resistant depression. Psychother Psychosom. 2016;85(2):99–110.
    pubmed_reference_list
11. Cladder-Micus MB, Speckens AEM, Vrijsen JN, T Donders AR, Becker ES, Spijker J. Mindfulness-based cognitive therapy for patients with chronic, treatment-resistant depression: a pragmatic randomized controlled trial. Depress Anxiety. 2018;35(10):914–24.
    pubmed_reference_list
12. Michalak J, Schultze M, Heidenreich T, Schramm E. A randomized controlled trial on the efficacy of mindfulness-based cognitive therapy and a group version of cognitive behavioral analysis system of psychotherapy for chronically depressed patients. J Consult Clin Psych. 2015;83(5):951–63.
    pubmed_reference_list
13. Chiesa A, Castagner V, Andrisano C, Serretti A, Mandelli L, Porcelli S, et al. Mindfulness-based cognitive therapy vs. psycho-education for patients with major depression who did not achieve remission following antidepressant treatment. Psychiat Res. 2015;226(2–3):474–83.
    pubmed_reference_list
14. Garcia A, Yáñez AM, Bennasar-Veny M, Navarro C, Salva J, Ibarra O, et al. Efficacy of an adjuvant non-face-to-face multimodal lifestyle modification program for patients with treatment-resistant major depression: a randomized controlled trial. Psychiatry Res. 2023;319:114975.
    pubmed_reference_list
15. Barnhofer T, Dunn BD, Strauss C, Ruths FA, Barrett B, Ryan M, et al. Mindfulness-based cognitive therapy versus treatment as usual after non-remission with NHS Talking Therapies high-intensity psychological therapy for depression: a UK-based clinical effectiveness and cost-effectiveness randomised, controlled, superiority trial. Lancet Psychiatry. 2025;12(6):433–46.
    pubmed_reference_list
16. Mathew T, Nordström K. Comparison of one‐step and two‐step meta‐analysis models using individual patient data. Biom J. 2010;52(2):271–87.
    pubmed_reference_list
17. Clarke MJ. Individual patient data meta-analyses. Best Pr Res Clin Obstet Gynaecol. 2005;19(1):47–55.
    pubmed_reference_list
18. Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ. 2010;340:c221.
    pubmed_reference_list
19. Jones AP, Riley RD, Williamson PR, Whitehead A. Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clin Trials. 2009;6(1):16–27.
    pubmed_reference_list
20. Stewart LA, Clarke M, Rovers M, Riley RD, Simmonds M, Stewart G, et al. Preferred reporting items for a systematic review and meta-analysis of individual participant data: the PRISMA-IPD statement. Jama. 2015;313(16):1657–65.
    pubmed_reference_list
21. Löfholm CA, Brännström L, Olsson M, Hansson K. Treatment‐as‐usual in effectiveness studies: what is it and does it matter? Int J Soc Welf. 2013;22(1):25–34.
    pubmed_reference_list
22. Korten NCM, Comijs HC, Lamers F, Penninx BWJH. Early and late onset depression in young and middle aged adults: differential symptomatology, characteristics and risk factors? J Affect Disord. 2012;138(3):259–67.
    pubmed_reference_list
23. Devanand DP, Adorno E, Cheng J, Burt T, Pelton GH, Roose SP, et al. Late onset dysthymic disorder and major depression differ from early onset dysthymic disorder and major depression in elderly outpatients. J Affect Disord. 2004;78(3):259–67.
    pubmed_reference_list
24. Wahl I, Löwe B, Bjorner JB, Fischer F, Langs G, Voderholzer U, et al. Standardization of depression measurement: a common metric was developed for 11 self-report depression measures. J Clin Epidemiol. 2014;67(1):73–86.
    pubmed_reference_list
25. Furlan AD, Pennick V, Bombardier C, van Tulder M; Editorial Board Cochrane Back Review Group . 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine. 2009;34(18):1929–41.
    pubmed_reference_list
26. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
    pubmed_reference_list
27. Miguel C, Harrer M, Karyotaki E, Sakher E, Sakata M, Furukawa TA, et al. Operationalization of Cochrane’s Risk of Bias 2 Tool (RoB 2) in the context of psychotherapy trials. medRxiv. 2025.
    pubmed_reference_list
28. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606–13.
    pubmed_reference_list
29. Löwe B, Unützer J, Callahan CM, Perkins AJ, Kroenke K. Monitoring depression treatment outcomes with the Patient Health Questionnaire-9. Med Care. 2004;42(12):1194–201.
    pubmed_reference_list
30. Hudgens S, Floden L, Blackowicz M, Jamieson C, Popova V, Fedgchin M, et al. Meaningful change in depression symptoms assessed with the Patient Health Questionnaire (PHQ-9) and Montgomery-Åsberg Depression Rating Scale (MADRS) among patients with treatment resistant depression in two randomized, double-blind, active-controlled trials of Esketamine nasal spray combined with a new oral antidepressant. J Affect Disord. 2021;281:767–75.
    pubmed_reference_list
31. Turkoz I, Alphs L, Singh J, Jamieson C, Daly E, Shawi M, et al. Clinically meaningful changes on depressive symptom measures and patient‐reported outcomes in patients with treatment‐resistant depression. Acta Psychiatr Scand. 2021;143(3):253–63.
    pubmed_reference_list
32. Han S, Zhou X. Defining estimands in clinical trials: a unified procedure. Stat Med. 2023;42(12):1869–87.
    pubmed_reference_list
33. Lunn D, Jackson C, Best N, Thomas A, Spiegelhalter D. The BUGS book - a practical introduction to Bayesian analysis. CRC Press; 2019.
    pubmed_reference_list
34. Goligher EC, Heath A, Harhay MO. Bayesian statistics for clinical research. Lancet. 2024;404(10457):1067–76.
    pubmed_reference_list
35. Cuijpers P, Turner EH, Koole SL, van Dijke A, Smit F. What is the threshold for a clinically relevant effect? The case of Major Depressive Disorders. Depress Anxiety. 2014;31(5):374–8.
    pubmed_reference_list
36. Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1–67.
    pubmed_reference_list
37. Fisher DJ, Carpenter JR, Morris TP, Freeman SC, Tierney JF. Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach? BMJ. 2017;356:j573.
    pubmed_reference_list
38. Barnhofer T, Crane C, Hargus E, Amarasinghe M, Winder R, Williams JMG. Mindfulness-based cognitive therapy as a treatment for chronic depression: a preliminary study. Behav Res Ther. 2009;47(5):366–73.
    pubmed_reference_list
39. Foroughi A, Sadeghi K, Parvizifard A, Parsa Moghadam A, Davarinejad O, Farnia V, et al. The effectiveness of mindfulness-based cognitive therapy for reducing rumination and improving mindfulness and self-compassion in patients with treatment-resistant depression. Trends Psychiatry Psychother. 2020;42(2):138–46.
    pubmed_reference_list
40. Hamidian S, Omidi A, Mousavinasab SM, Naziri G. Comparison of the effect of mindfulness-based cognitive therapy accompanied by pharmacotherapy with pharmacotherapy alone in treating dysthymic patients. Iran Red Crescent Me. 2013;15(3):239–44.
    pubmed_reference_list
41. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23(1):56–62.
    pubmed_reference_list
42. Beck A, Steer R, Brown G. Manual for the beck depression Inventory-II. Psychological Corporation; 1996.
    pubmed_reference_list
43. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477–86.
    pubmed_reference_list
44. Pigott HE, Kim T, Xu C, Kirsch I, Amsterdam J. What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol. BMJ Open. 2023;13(7):e063095.
    pubmed_reference_list
45. Gu J, Strauss C, Bond R, Cavanagh K. How do mindfulness-based cognitive therapy and mindfulness-based stress reduction improve mental health and wellbeing? A systematic review and meta-analysis of mediation studies. Clin Psychol Rev. 2015;37:1–12.
    pubmed_reference_list
46. van der Velden AM, Kuyken W, Wattar U, Crane C, Pallesen KJ, Dahlgaard J, et al. A systematic review of mechanisms of change in mindfulness-based cognitive therapy in the treatment of recurrent major depressive disorder. Clin Psychol Rev. 2015;37:26–39.
    pubmed_reference_list
47. Sahker E, Furukawa TA, Luo Y, Ferreira ML, Okazaki K, Chevance A, et al. Estimating the smallest worthwhile difference of antidepressants: a cross-sectional survey. BMJ Ment Health. 2024;27:e300919–8.
    pubmed_reference_list
48. Barnhofer T, Dunn BD, Strauss C, Ruths F, Barrett B, Ryan M, et al. A randomised controlled trial to investigate the clinical effectiveness and cost effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) for depressed non-responders to Increasing Access to Psychological Therapies (IAPT) high-intensity therapies: study protocol. Trials. 2023;24(1):43.
    pubmed_reference_list

Dokładne dopasowania identyfikatorów

Nie znaleziono dopasowań w tej grupie.

Kandydaci do ręcznej kontroli

• MBCT w zapobieganiu nawrotom depresji: metaanaliza danych indywidualnych · src_mbct_kuyken_2016_ipd · PROBABLE_MATCH · rok 2016

Konflikty

Nie znaleziono dopasowań w tej grupie.

Podobieństwo nie scala rekordów i nie potwierdza tożsamości publikacji.

Zakres: jawne relacje claims[].source_ids[] powiązane z publikacją.